BOLD — Boundless Bio Income Statement
0.000.00%
HealthcareSmall Cap
- $86.13m
- -$18.75m
Annual income statement for Boundless Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|
Period Length: | 12 M | 12 M | 12 M |
Source: | PROSPECTUS/A | PROSPECTUS/A | PROSPECTUS/A |
Standards: | USG | USG | USG |
Status: | Final | Final | Final |
Total Revenue | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||
Research And Development | |||
Total Operating Expenses | 25.3 | 46.5 | 54.8 |
Operating Profit | -25.3 | -46.5 | -54.8 |
Total Net Non Operating Interest Income / Expense | |||
Other Net Non Operating Costs | |||
Net Income Before Taxes | -25.2 | -45.9 | -49.4 |
Net Income After Taxes | -25.2 | -45.9 | -49.4 |
Net Income Before Extraordinary Items | |||
Net Income | -25.2 | -45.9 | -49.4 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||
Income Available to Common Shareholders Including Extraordinary Items | |||
Diluted Net Income | -25.2 | -45.9 | -49.4 |
Diluted Weighted Average Shares | |||
Basic EPS Including Extraordinary Items | |||
Diluted EPS Including Extraordinary Items | |||
Diluted EPS Excluding Extraordinary Items | |||
Normalised Income Before Taxes | |||
Normalised Income After Taxes | |||
Normalised Income Available to Common Shareholders | |||
Diluted Normalised EPS | -1.13 | -2.06 | -2.22 |
Dividends per Share |